DENTSPLY SIRONA Inc header image

DENTSPLY SIRONA Inc

XRAY

Equity

ISIN US24906P1093 / Valor 31773200

NASDAQ (2024-09-18)
USD 26.71+0.07%

DENTSPLY SIRONA Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

DENTSPLY SIRONA Inc is a global leader in the manufacturing of professional dental products and technologies, working in collaboration with partners to develop innovative solutions for dental professionals worldwide. With a mission to transform dentistry and improve oral health on a global scale, the company is dedicated to empowering dental practices, clinics, laboratories, and distributors to deliver top-quality dental care to patients. DENTSPLY SIRONA's research division plays a key role in driving the development of next-generation dental solutions, reflecting the company's commitment to advancing the field of dentistry.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (07.08.2024):

Net Sales

DENTSPLY SIRONA Inc. reported net sales of $953 million for the first quarter of 2024, reflecting a decrease of 2.6% compared to the same period in 2023. Organic sales also saw a decline of 1.9% year-over-year.

Net Income

The company achieved a GAAP net income of $18 million, or $0.09 per share, in Q1 2024. This is a significant improvement compared to a net loss of $19 million, or ($0.09) per share, in the first quarter of 2023.

Adjusted Earnings

Adjusted earnings per diluted share for DENTSPLY SIRONA Inc. in Q1 2024 were $0.42, up from $0.39 in the same quarter of the previous year. The adjusted EBITDA margin was 16.8%, slightly higher than the 16.5% reported in Q1 2023.

Cash Flow and Liquidity

Operating cash flow for the first quarter of 2024 was $25 million, a notable improvement from the negative $21 million reported in Q1 2023. The company also paid $29 million in dividends during this period and had $291 million in cash and cash equivalents as of March 31, 2024.

2024 Outlook

DENTSPLY SIRONA Inc. is maintaining its 2024 outlook for organic sales growth in the range of flat to up 1.5%, and adjusted EPS in the range of $2.00 to $2.10. However, the company expects these metrics to trend towards the low end of the provided ranges due to the current macroeconomic environment.

Summarized from source with an LLMView Source

Key figures

-24.8%1Y
-56.4%3Y
-46.4%5Y

Performance

28.8%1Y
31.2%3Y
34.5%5Y

Volatility

Market cap

5410 M

Market cap (USD)

Daily traded volume (Shares)

1,289,911

Daily traded volume (Shares)

1 day high/low

27.47 / 26.515

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Hasegawa Kouryou KK
Hasegawa Kouryou KK Hasegawa Kouryou KK Valor: 372531
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.59%JPY 3,010.00
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc Alnylam Pharmaceuticals Inc Valor: 1806798
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.48%USD 273.15
BeiGene Ltd
BeiGene Ltd BeiGene Ltd Valor: 30165310
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.12%USD 197.28
Amicus Therapeutics Inc
Amicus Therapeutics Inc Amicus Therapeutics Inc Valor: 2644388
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.59%USD 10.91
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC Jazz Pharmaceuticals PLC Valor: 14769757
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.78%USD 109.56
Laboratorios Farmaceuticos Rovi, SA
Laboratorios Farmaceuticos Rovi, SA Laboratorios Farmaceuticos Rovi, SA Valor: 3591807
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.07%EUR 73.95
Almirall SA
Almirall SA Almirall SA Valor: 3180354
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.12%EUR 8.51
Pharma Mar SA
Pharma Mar SA Pharma Mar SA Valor: 56130572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.65%EUR 45.26
ModivCare Inc
ModivCare Inc ModivCare Inc Valor: 59168951
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.30%USD 13.50
Novo Nordisk A/S
Novo Nordisk A/S Novo Nordisk A/S Valor: 129508879
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.35%DKK 882.20